Featuring latest Drug Developments and Treatment Protocols and also Updates about the Pharmaceutical Industry , both in Thailand and abroad, latest USFDA and Thai FDA approvals and also Corporate News with regards to various Pharma companies.
Source: Medical News -NSAIDs-Heart Failure Sep 07, 2022 21 days ago
A new study by Danish researchers the Copenhagen University Hospital in Denmark has found that the usages of common NSAIDs (non-steroidal anti-inflammatory drugs) like Ibuprofen and Diclofenac by diabetics were linked to a higher risk of heart failure.
The study findings were presented during the recent European Society of Cardiology annual congress or ESC Congress 2022 and will be publis...
Source: Drug News - GLP-1 Receptor Agonists Drugs Sep 05, 2022 23 days ago
Drug News: Medical researchers from the U.S FDA have discovered that diabetics taking glucagon-like peptide-1 (GLP-1) receptor agonists drugs like exenatide, dulaglutide, semaglutide and lixisenatide have a higher risk of developing acute cholecystitis and even higher risk of death!
The study team conducted a detailed meta-analysis from data of the of U.S FDA's reporting system for ad...
Source: Colchicine-Heart Failure Jun 20, 2022 3 months ago
A new study by medical researchers from the University of Virginia-USA has found that the common and cheap drug that is used to treat gout- Colchicine, also helps improve the survival rates of heart failure patients.
Considering that the incidences of heart failures has increased tremendously during the COVID-19 pandemic due to suspected links between the SARS-CoV-2 virus and the direct and indir...
Source: Thailand Medical -Molnupiravir-COVID-19 May 08, 2022 5 months ago
Despite growing reports by many physicians around the world about a variety of adverse effects from patients who are treated with molnupiravir, the mutagenic drug that was approved by the non-credible U.S. FDA to treat COVID-19 and as usual was adopted by the stupid health authorities from various countries that emulates everything that America does, the drug is still being used by many stupid doc...
Source: Cyproterone Acetate Feb 05, 2022 8 months ago
A new study by researchers from University of Bristol-UK, National University of Singapore, University of Cambridge and Addenbrooke’s Hospital-UK and the National University Hospital-Singapore has alarmingly found that the hormone drug Cyproterone Acetate increases the risk developing benign brain tumors or meningiomas especially if used for long periods of time or in high doses.
Cyproter...
Source: Blood Thinners-COVID-19 Oct 02, 2021 1 year ago
Blood Thinners-COVID-19: A new study by researchers from University of Minnesota-USA and Basel University-Switzerland has found that outpatients with COVID-19 who were on outpatient blood thinners at the time of diagnosis experienced a 43% reduced risk of hospitalization.
The study focused on COVID-19 positive patients who have been taking prescribed anticoagulant class rugs including warfarin, a...
Source: Pulmonary Fibrosis Sep 01, 2021 1 year ago
A new breakthrough study by researchers from University of Alabama at Birmingham-USA has found that the drug Venetoclax used to treat adult patients with Chronic Lymphocytic Leukemia (CLL) could be repurposed to reverse lung fibrosis after successful mouse model drug trials.
Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymp...
Source: COVID-19 Drugs-Fluvoxamine Aug 14, 2021 1 year ago
COVID-19 Drugs: Fluvoxamine, an inexpensive anti-depressant drug is now emerging as a potential candidate to be repurposed to treat COVID-19.
Speculations are adrift that Canada might be the first country to approve its usage to treat COVID-19 followed by the United States, India, Brazil and South Africa.
Fluvoxamine, sold under the brand name Luvox among others, is an antid...
Remdesivir the controversial drug that was deemed to be ineffective in WHO’S SolidarityTrial (https://www.thailandmedical.news/news/latest-who-s-solidarity-drug-trial-shows-that-remdesivir-is-not-the-least-effective-in-treating-covid-19) but is still being approved as a drug to treat COVID-19 under EUA status in the United States by the no longer credible US FDA is now facing more backlash a...
Cancer Drugs: Pembrolizumab, an immunotherapy drug has been recently approved by the U.S. FDA as a first-line treatment for patients with certain types of advanced colorectal cancer. This is the 9th FDA approval supported by Stand Up To Cancer® (SU2C) research.
Individuals newly diagnosed with advanced or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (d...
Pharma News: American biotech company that is linked to the corrupted Trump administration Regeneron, has another of its clinical trials halted over the weekend due to fatal adverse reactions to the monoclonal antibody drug garetosmab (REGN2477).
Only about 4 days ago, another clinical trial involving another monoclonal antibody drug to treat severe COVID-19 patients was also stopped due ...
Drugs News: A new study by researchers from the Universities of Edinburgh, Birmingham, Oxford and Nottingham have found the drug Gabapentin that is regularly used to treat chronic pelvic pain in women has been found to be no more effective than a placebo.
Chronic pelvic pain is estimated to affect 2–24% of women worldwide, and is associated with substantially reduced quality of life...
HIV Drug News: Researchers at the George Washington University in a new study have discovered that Fingolimod, a US FDA-approved immunosuppressive drug used to treat multiple sclerosis flare-ups, may be used to effectively block HIV infection and reduce the latent virus reservoir.
The research findings were published in the journal: PLOS Pathogens. https://journals.plos.org/plospathogens/...
TB Treatments: New protocols involving the drugs Bedaquiline and Delamanid for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many individuals with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.
The clinical trial results, based on...
Source: Diabetes And Canagliflozin Aug 09, 2020 2 years ago
Diabetes And Canagliflozin: A serious drug interaction between canagliflozin (Invokana) and rosuvastatin (Crestor) was thought to cause liver and muscle toxicity (myotoxoicty) in a female patient in Canada, according to a new published case report.
The case report was published in the medical journal: Annals of Internal Medicine as reported by Dr David Juurlink, MD, PhD, of Sunnybrook Health Sc...
Source: Multiple Sclerosis: Aug 06, 2020 2 years ago
Multiple Sclerosis: A recently completed phase 3, multicenter clinical trial has found that an immune-modulating drug can silence inflammatory disease activity in a large majority of patients with relapsing multiple sclerosis (RMS), the most common form of the illness, in which symptoms wax and wane.
Multiple Sclerosis or MS is an autoimmune disease in which the body's immu...
Head Lice: A novel prescription head lice treatment, developed by University of Melbourne Associate Professor Dr Vern Bowles, has been given Food and Drug Administration (FDA) approval, allowing it to be sold in the U.S.
The new treatment, Xeglyze, was developed by Hatchtech, an Australian pharmaceutical company and will be commercialised by Dr. Reddy's Laboratories.
Hugh Alsop, ...
Sports Medicine: Researchers from Western Norway University of Applied Sciences and the Norwegian University of Sport and Physical Education have discovered that a type of asthma drug, known as ß2-agonists, can boost sprint and strength performance in athletes who don't have the respiratory condition.
Their research findings have been published in the British Journal of Spo...
Medicine Alert: Pennsylvania State University researchers along with scientists from La Jolla Institute for Immunology-California and Weill Cornell Medicine-Qatar, have found that in rats and human cells in vitro, LCCBs cause changes in blood vessels known as vascular remodeling that reduce blood flow and increase pressure and could potentially lead to heart failure.
The study finding...
Source: COVID-19 Warnings- Captopril Jul 07, 2020 2 years ago
COVID-19 Warnings: A US based study involving researchers from University of Missouri Kansas City School of Pharmacy, Kansas State University and North Carolina State University has found that the high blood pressure drug Captopril to be associated with a higher rate of pulmonary adverse reactions in patients with diabetes than that of other ACE inhibitors or angiotensin receptor blockers (ARBs).
...
Source: Octreotide and Acromegaly Jun 27, 2020 2 years ago
Octreotide and Acromegaly: The American Food and drug administration has approved the first and only oral form of somatostatin analog octreotide ( tradename: Mycapssa) as a long-term maintenance therapy for individuals with acromegaly.
The drug Octreotide by Chiasma pharmaceuticals is the first product approved by the FDA using Chiasma's Transient Permeability Enhancer (TPE) tec...
Source: Multiple Sclerosis Jun 18, 2020 2 years ago
Multiple Sclerosis: Medical researchers from the Kessler Foundation recently conducted a comprehensive review of pharmacologic agents used in the treatment of multiple sclerosis, seeking evidence for efficacy for the cognitive dysfunction experienced by more than half of affected individuals and found that most of the prescribed drugs do not work.
The research findings were published in the...
Source: Vildagliptin Versus Metformin Jun 17, 2020 2 years ago
Vildagliptin an oral anti-hyperglycemic agent that goes by the trade name Galvus showed similar protective effects as metformin on the beta-cell function, reduced insulin resistance, and blood sugar levels in newly diagnosed Asian Indians with type 2 diabetes (T2D), according to a recent study.
The research trial further found that there was an improved insulin sensitivity in patients treated wi...
Pharmaceuticals: The US Food and Drug Administration has approved nivolumab (OPDIVO) by Bristol-Myers Squibb for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Proof for efficacy was investigated in ATTRACTION-3 (NCT02569242), a multicenter, randomized (1:1), active-controlled,...
Source: Metformin and Diabetes May 30, 2020 2 years ago
Metformin: The US FDA has issued warnings that many brands and versions of the drug Metformin that is used by diabetics in the US and around the world have been found to be contaminated with a carcinogenic compound called N-Nitrosodimethylamine.
The U.S. health regulators have started telling five drugmakers to recall their versions of a widely used diabetes medication after laboratory te...
Source: Thailand Medical News Jan 03, 2020 3 years ago
In a latest development, the European Commission (EC) has approved Johnson & Johnson subsidiary Janssen’s Spravato (esketamine) nasal spray for treatment-resistant major depressive disorder.
Spravato or Esketamine is an antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor and is similar in composition to illegal drug ketamine; Janssen has a risk management plan related to ...
Source: Thailand Medical News Dec 14, 2019 3 years ago
Combined analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC). Results of the trials STARTRK-1 (NCT02097810), STARTRK-2 (NCT02568267), and ALKA, show 77 percent response rate to entrectinib in 53 ...
Source: Thailand Medical News Dec 11, 2019 3 years ago
A new research by pediatrics and migraine specialists from the University of Medical Sciences, Tehran show that Cinnarizine and Sodium Valproate are effective as the preventive agents of pediatric migraine in young children and teenagers.
The study article entitled "Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: A randomized double-blind placebo-controlled t...
Source: Thailand Medical News Dec 02, 2019 3 years ago
Pharma Conglomerate, AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC).
Small Cell Lung Cancer is an aggressive, fast-growing form of lung cancer that r...
Source: Thailand Medical News Nov 29, 2019 3 years ago
The US FDA (Food and Drug Administration) has approved South Korean company SK Chemicals’ patch-type Alzheimer’s drug, SID710.
The drug which has already secured approval in the European Union in 2013, is the generic version of Novartis’ Exelon Patch for the treatment of dementia symptoms associated with Alzheimer’s disease.
The approval marks the first time...
Source: Thailand Medical News Nov 22, 2019 3 years ago
Thailand Pharma News
The US FDA has granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).1
The Project Orbis, a collaboration between the United States, Australia, and Canada, provides a framework for concurrent submission and review of oncology pharmaceutical ap...
Source: Thailand Medical News Nov 20, 2019 3 years ago
The US FDA (Food and Drug Administration ) has approved Fetroja (cefiderocol), an antibacterial drug for treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI), including kidney infections caused by susceptible Gram-negative microorganisms, who have limited or no alternative treatment options.
Dr John Farley, acting director of the Office of Infecti...
Source: Thailand Medical News Nov 16, 2019 3 years ago
The US Food and Drug Administration approved Novartis AG's Adakveo (crizanlizumab) as new medicine that can help reduce extremely painful sickle cell disease flare-ups for patients 16 and older. The monthly infusion, which halves occurrences of sickle cell pain episodes, will carry a list price of roughly US$82,000 to US$114,000 per year, depending on dosing.
Unfortunately, sickle cell dise...
Source: Thailand Medical News Nov 10, 2019 3 years ago
The US FDA approved a record-breaking 59 novel drugs in 2018 for a range of diseases, bringing hope to scores of health sufferers around the world. This number was a more than twofold increase from a decade prior, which saw only 24 new drug approvals. And while this rise in the production and dissemination of new biological agents and products is good news for the advancement of global h...
Source: Thailand Medical News Nov 09, 2019 3 years ago
The U.S. Food and Drug Administration has granted approval for Reblozyl (luspatercept-aamt) to be used for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Dr Richard Pazdur, M.D., director of the US FDA's Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in th...
Source: Thailand Medical News Oct 26, 2019 3 years ago
New findings from the LIBERTY ASTHMA QUEST trial show that add-on dupilumab (Dupixent) showed symptomatic benefit for patients with both early-onset and later-onset uncontrolled asthma.
In trial data published in the Chest Journal, the interleukin 4 and 13 (IL-4; IL-13) targeting monoclonal antibody showed an associated reduction of severe exacerbations and improved lung function in patien...
Source: Thailand Medical News Oct 25, 2019 3 years ago
The US FDA has approved a new indication for the SGLT2 inhibitor canagliflozin made by Janssen Pharmaceuticals to reduce the risk for end-stage renal disease, worsening of kidney function, cardiovascular death and hospitalization for heart failure among adults with type 2 diabetes and diabetic kidney disease. Type 2 diabetes is the leading cause of kidney disease in the world, and the fifth fastes...
Source: Thailand Medical News Oct 23, 2019 3 years ago
Trikafta (elexacaftor/ivacaftor/tezacaftor) from Vertex Pharmaceuticals is the first triple combination therapy to be approved by the US FDA and made available to treat patients with the most common cystic fibrosis mutation. Its list price is US$350,000 a year, same as one of the maker's earlier treatments for the genetic disease.
Trikafta has been approved for patients aged 12 an...
Source: Thailand Medical News Oct 22, 2019 3 years ago
A study by the London School of Hygiene & Tropical Medicine has shown that Tranexamic Acid, a low cost and widely available drug could reduce deaths in traumatic brain injury patients by as much as 20%, depending on the severity of injury. The findings were published in the The Lancet. The researchers say that tranexamic acid, (TXA), a drug that prevents bleeding into the brain by inhibit...
Source: Thailand Medical News Oct 20, 2019 3 years ago
A new flu drug by Genentech, Xofluza (baloxavir marboxil) has been granted US Food and Drug Administration (FDA) approval for a supplemental New Drug Application (NDA).
The US FDA approval has been given for the indication of acute, uncomplicated influenza, or flu, in individuals aged 12 and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-rela...
Source: Thailand Medical News Oct 14, 2019 3 years ago
New study shows that ranitidine is an unstable molecule that breaks down under different conditions into the carcinogen N-nitrosodimethylamine (NDMA).
Online pharmacy Valisure is claiming that the Zantac is carcinogenic with N-nitrosodimethylamine (NDMA); that is a byproduct of the breakdown of the ranitidine molecule. The company, which performs its own testing on drugs it carries,...
Source: Thailand Medical News Sep 23, 2019 3 years ago
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego have discovered that Nilotinib (Tasigna), a drug used to treat chronic myeloid leukemia (CML) appears to be more effective at stopping a type of brain cancer called medulloblastoma in animal models than existing treatments for the deadly pediatric brain tumor.
Nilotinib is a type...
Source: Thailand Medical News Sep 21, 2019 3 years ago
The US FDA has approved supplemental new drug applications (NDAs) to expand the use of the drugs Pifeltro and Delstrigo as inclusions in the treatment of patients who are virologically suppressed on a stable ART regimen with no previous history of treatment failure. The approvals provide HIV patients with a wider option of drugs for their ART regiments.
The new approval is for adults curr...
Source: Thailand Medical News Sep 02, 2019 3 years ago
Researchers from Brigham Hospital and Greater Paris University Hospitals presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS), during the current European Society of Cardiology Congress 2019.The clinical trial evaluated whether adding ticagrelor to aspirin improves outcomes for patients with stable coronary art...
Source: Thailand Medical News Aug 16, 2019 3 years ago
The US FDA announced this week the approval of pretomanid tablets as part of a 3 drug combo protocol for the treatment regimen for the most deadly strain of tuberculosis which is fast spreading globally with increasing occurrence rates.
Pretomanid (PA-824) tablets were approved to be used as part of a three drug combination protocol along with bedaquiline and linezolid in patients with extensive ...
Source: Thailand Medical News Aug 03, 2019 3 years ago
The European Commission on Ist Of August had granted marketing authorisation for two new methods of administering Nucala (mepolizumab): a pre-filled pen and a pre-filled safety syringe. This is the only monthly dose anti-IL5 biologic approved in Europe that patients with severe eosinophilic asthma can self-after getting it prescribed by a pulmonologists. The original lyophilised version remains av...
Source: Thailand Medical News Jul 04, 2019 3 years ago
The US FDA has approved a new drug, Selinexor to treat patients with relapsed or refractory multiple myeloma, overruling a panel of external cancer experts who expressed concerns about its toxicity. The FDA approval was under an accelerated, or conditional, approval based on a single-arm clinical trial showing a 25% tumor response rate. The patients enrolled in the clinical trial...
Source: Thailand Medical News Jun 01, 2019 3 years ago
Vascepa ( Icosapent Ethyl) by Amarin Group Of Companies, (New Jersey, US) is the only EPA prescription Omega-3 clinically proven to lower very high triglycerides in adults by 33%, without raising bad cholesterol (LDL-C). Unlike VASCEPA, common Omega Oil and fish oil supplements are not pure EPA and most also contain DHA which can raise bad cholesterol.
The produc...
The U.S. FDA has approved Piqray (alpelisib) tablets, to be used in combination with the approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (only as detected by an FDA-approved test) following progression on or after an end...
Source: Thailand Medical News May 19, 2019 3 years ago
US FDA has approved the Dalteparin Sodium, (Fragmin) which is a low molecular weight heparin(LMWH) for the treatment of of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older.
Venous thromboembolism (VTE) is a condition in which a blood clot forms most often in the deep veins of the leg, groin or arm (known as deep vein thrombosis, DVT) ...
The U.S. Food and Drug Administration approved Benlysta (belimumab) intravenous (IV) infusion for treatment of children with systemic lupus erythematosus (SLE) - often referred to as simply "lupus" - a serious chronic disease that causes inflammation and damage to various body tissues and organs. This is the first time that the FDA has approved a treatment for pediatric patients with SLE...
French pharmaceutical giant Sanofi on Friday said the European Medicines Agency had conditionally approved its anti-cancer drug Libtayo, the first drug of its kind to be authorised for use in the EU. The drug, also known as CEMIPLIMAB-RWLC is used for for treatment of Advanced Cutaneous Squamous Cell Carcinoma
The tumour-reducing drug is aimed at patients with the second most common form of ski...
Source: American College of Physicians Apr 24, 2019 3 years ago
In the Diabetes Prevention Program (DPP) clinical trial and its long-term follow-up study, among the persons who lost at least 5 percent of their body weight during the first year, long-term maintenance of weight loss was more likely if they had been assigned to treatment with metformin than with placebo or lifestyle intervention. Being older and losing a greater amount of weight in the first year...
Source: Stanford Medicine Apr 16, 2019 4 years ago
A new landmark clinical trial shows that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease.
"For the first time in 18 years, we have a therapy for patients with Type 2 diabetes and chronic kidney disease that decreases kidney failure," said Kenneth Mahaffey, MD, professor of medicine at the Stanford University School of Medicine and co...
The U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.
"Today's approval of Cimzia fulfills an unmet need for pa...
.jpg)
.jpg)
